PTS36-LD3
The cell line is not validated yet.
OSRi018-A-2
General
Cell Line |
|
| hPSCreg name | OSRi018-A-2 |
| Cite as: | OSRi018-A-2 |
| Alternative name(s) |
PTS36-LD3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 24th October 2025 |
| User feedback | |
Provider |
|
| Generator |
Ospedale San Raffaele (OSR)
Contact:
Ospedale San Raffaele (OSR) |
| Owner | Ospedale San Raffaele (OSR) |
| Distributors | |
| Derivation country | Italy |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasic |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Ethics
Also have a look at the ethics information for the parental line
OSRi018-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
OSRi018-A.
|
|
Reprogramming method |
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
No characterisation data could be found for this subclone. Please open parental cell line OSRi018-A .Genotyping
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification
| Disease/phenotype related modifications |
|

Login to share your feedback, experiences or results with the research community.